Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4282-4289

  McCaffery, Ian ^a   Tudor, Yanyan ^a   Deng, Hongjie ^a   Tang, Rui ^a   Suzuki, Samuel ^a   Badola, Sunita ^a   Kindler, Hedy L ^c   Fuchs, Charles S ^b   Loh, Elwyn ^a   Patterson, Scott D ^a   Chen, Li ^a   Gansert, Jennifer L ^a  

^a AMGEN INC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CONATUMUMAB; GANITUMAB; GEMCITABINE; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN P53; RINFABATE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; DEOXYCYTIDINE; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PTEN PROTEIN, HUMAN; RAS PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; DEOXYCYTIDINE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, IGF TYPE 1; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881246665     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1840     Document Type: Article

References (33)

1. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005;128:1642-54.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA: Cancer J Clin 2010;60:277-300.
3. Tarceva (erlotinib) prescribing information, Genentech. Accessed 6/18/2013. Available at: (http://www.gene.com/download/pdf/tarceva-prescribing. pdf)
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
5. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12.
6. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44.
7. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
8. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
9. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 2003;22: 6589-97.
10. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993;90:11217-21.
11. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009;8:1095-105.
12. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Rev 1997;18:801-31.
13. Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer 2009;10:262-72.
14. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
15. Catalogue of somatic mutations in cancer; [Accessed 27 Mar 2012]. Available from (www.sanger.ac.uk/perl/genetics/CGP/cosmic? actionbyhist& ssNS&snpancreas&s3&hnNS&hncarcinoma.)
16. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004;382:1-11.
17. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004;15:171-6.
18. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63.
19. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr., Rocha-Lima CM, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012;23:2834-42.
20. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7.
21. Kendall M, Stuart A. The Advanced Theory of Statistics. 4th ed. New York, NY: Macmillan; 1977.
22. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56:337-44.
23. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012;18:40-50.
24. MaJ, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colerectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF binding protein-3. J Natl Cancer Inst 1999;91:620-5.
25. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6.
26. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998;351:1393-6.
27. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
28. Rohrmann S, Grote VA, Becker S, Rinaldi S, Tjonneland T, Roswall N, et al. Concentrations of IGF-1 and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2012;106:1004-10.
29. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, et al. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 2007;67:7923-8.
30. Douglas JB, Silverman DT, Pollack MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-1, IGF-2, IGFBP-3, and IGF-1/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2010;19:2298-306.
31. Lin Y, Tamakoshi A, Kikuchi S, Yagyu K, Obata Y, Ishibashi T, et al. Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer 2004;110:584-8.
32. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2011;104:68-74.
33. IMMULITE-IGFBP-3 package insert. Accessed 10/19/2012. Available at: (http://www.medical.siemens.com/siemens/en-GLOBAL/gg-diag-FBAs/files/ package-inserts/immulite/Growth/lkgb-6.pdf.)